Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Dec 12 (Reuters) - Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, ...

A drug approved to help slow the progression of Alzheimer’s is giving an Oklahoma couple hope. The drug is only for patients ...

Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

As researchers continue to advance the understanding of Alzheimer’s disease, new treatment options are offering hope for ...

Get insights on Biogen’s Leqembi sales outlook, clinical value, risks, and what new drug approvals may mean for investors.

Investing.com -- Moody’s Ratings has affirmed Eli Lilly and Company’s Aa3 senior unsecured notes ratings and long-term issuer rating while revising the outlook to positive from stable, the rating ...

Experts at a roundtable in Boston, Massachusetts, on November 3, 2025, discussed improving early Alzheimer disease diagnosis, addressing workforce and equity gaps, and expanding access to new ...